UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 41

Sortiert nach

A therapeutically targetable mechanism of BCR-ABL-independent imatinib resistance in chronic myeloid leukemia

Science translational medicine, 2014-09, Vol.6 (252), p.252ra121

2014

Link zum Volltext

Verfügbarkeit prüfen

Reducing the Risk for Transplantation-Related Mortality After Allogeneic Hematopoietic Cell Transplantation: How Much Progress Has Been Made?

Journal of clinical oncology, 2011-03, Vol.29 (7), p.805-813

2011

Link zum Volltext

Verfügbarkeit prüfen

Dasatinib treatment for Philadelphia chromosome‐positive leukemias

Cancer, 2009-04, Vol.115 (7), p.1381-1394

2009

Link zum Volltext

Verfügbarkeit prüfen

Ruxolitinib: a steroid sparing agent in chronic graft-versus-host disease

Bone marrow transplantation (Basingstoke), 2018-07, Vol.53 (7), p.826-831

2018

Link zum Volltext

Verfügbarkeit prüfen

Sustained Complete Molecular Remission After Discontinuation of Tyrosine Kinase Inhibitors in Blast-Phase Chronic Myeloid Leukemia

Journal of clinical oncology, 2016-03, Vol.34 (8), p.e68-e69

2016

Link zum Volltext

Verfügbarkeit prüfen

Does the frequency of molecular monitoring after tyrosine kinase inhibitor discontinuation affect outcomes of patients with chronic myeloid leukemia?

Cancer, 2017-07, Vol.123 (13), p.2482-2488

2017

Link zum Volltext

Verfügbarkeit prüfen

Predicting early blast transformation in chronic‐phase chronic myeloid leukemia: Is immunophenotyping the missing link?

Cancer, 2015-03, Vol.121 (6), p.872-875

2015

Link zum Volltext

Verfügbarkeit prüfen

Allogeneic transplantation for advanced acute myelogenous leukemia: The value of complete remission

Journal of clinical oncology, 2016-05, Vol.34 (15_suppl), p.7033-7033

2016

Link zum Volltext

Verfügbarkeit prüfen

Bosutinib treatment for Philadelphia chromosome-positive leukemias

Future oncology (London, England), 2014-02, Vol.10 (2), p.179-185

2014

Link zum Volltext

Verfügbarkeit prüfen

Chronic Myeloid Leukemia: What Every Practitioner Needs to Know in 2017

American Society of Clinical Oncology educational book, 2017, Vol.37 (37), p.468-479

2017

Link zum Volltext

Verfügbarkeit prüfen

Long-term bosutinib (BOS) for Philadelphia Chromosome–Positive (Ph+) advanced (ADV) chronic myeloid leukemia (CML) after prior tyrosine kinase inhibitor (TKI) failure

Journal of clinical oncology, 2015-05, Vol.33 (15_suppl), p.7068-7068

2015

Link zum Volltext

Verfügbarkeit prüfen

Costs associated with induction chemotherapy in adult acute myeloid leukemia (AML) managed in a tertiary care specialized unit

Journal of clinical oncology, 2016-05, Vol.34 (15_suppl), p.e18503-e18503

2016

Link zum Volltext

Verfügbarkeit prüfen

Five-year results of the ponatinib phase II PACE trial in heavily pretreated CP-CML patients (pts)

Journal of clinical oncology, 2017-05, Vol.35 (15_suppl), p.7012-7012

2017

Link zum Volltext

Verfügbarkeit prüfen

A phase I, first-in-human study of MGD006/S80880 (CD123 x CD3 DART) in AML/MDS

Journal of clinical oncology, 2017-05, Vol.35 (15_suppl), p.TPS7070-TPS7070

2017

Link zum Volltext

Verfügbarkeit prüfen

Early diagnosis of acute myeloid leukemia by computed tomography scan

Journal of clinical oncology, 2012-08, Vol.30 (23), p.e207-e208

2012

Link zum Volltext

Verfügbarkeit prüfen

Phase 1 dose escalation trial of ilorasertib, a dual Aurora/VEGF receptor kinase inhibitor, in patients with hematologic malignancies

Investigational new drugs, 2015-08, Vol.33 (4), p.870-880

2015

Link zum Volltext

Verfügbarkeit prüfen

Landmark analysis of overall survival (OS) in patients with chronic (CP) or accelerated (AP) phase chronic myeloid leukemia (CML) treated with omacetaxine mepesuccinate

Journal of clinical oncology, 2014-05, Vol.32 (15_suppl), p.7066-7066

2014

Link zum Volltext

Verfügbarkeit prüfen

Elevated blood pressure (BP) and adverse events (AEs) of hypertension (HTN) in ponatinib (PON) leukemia trials

Journal of clinical oncology, 2015-05, Vol.33 (15_suppl), p.7049-7049

2015

Link zum Volltext

Verfügbarkeit prüfen

Long-term bosutinib (BOS) in patients (pt) with chronic phase (CP) chronic myeloid leukemia (CML) after prior imatinib (IM) failure

Journal of clinical oncology, 2015-05, Vol.33 (15_suppl), p.7076-7076

2015

Link zum Volltext

Verfügbarkeit prüfen

4-year results of the ponatinib phase II PACE trial in patients (pts) with heavily pretreated leukemia

Journal of clinical oncology, 2016-05, Vol.34 (15_suppl), p.7013-7013

2016

Link zum Volltext

Verfügbarkeit prüfen

Predictors of performing response monitoring in patients with chronic-phase chronic myeloid leukemia (CP-CML) in a prospective observational study (SIMPLICITY)

Journal of clinical oncology, 2014-10, Vol.32 (30_suppl), p.116-116

2014

Link zum Volltext

Verfügbarkeit prüfen

Long-term evaluation of vascular toxicity in patients with Ph+ leukemias treated with bosutinib

Journal of clinical oncology, 2014-05, Vol.32 (15_suppl), p.7060-7060

2014

Link zum Volltext

Verfügbarkeit prüfen

Phase I dose escalation study of TG02 in patients with advanced hematologic malignancies

Journal of clinical oncology, 2012-05, Vol.30 (15_suppl), p.6577-6577

2012

Link zum Volltext

Verfügbarkeit prüfen

Omacetaxine mepesuccinate in chronic phase chronic myeloid leukemia (CML-CP): A post hoc analysis of myelosuppression

Journal of clinical oncology, 2013-05, Vol.31 (15_suppl), p.7073-7073

2013

Link zum Volltext

Verfügbarkeit prüfen

Evolution of bosutinib (BOS) toxicity in patients (pts) with Ph+ leukemia after resistance/intolerance to prior therapy

Journal of clinical oncology, 2013-05, Vol.31 (15_suppl), p.7099-7099

2013

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 41

Suche als RSS-Feed

Aktive Filter

ThemaHematologic And Hematopoietic Diseases

KollektionJournals@Ovid Full Text

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(41)
Mit Volltextzugriff
(38)

Publikationsform

Artikel
(41)

Sprache

Englisch
(41)
Japanisch
(3)

Erscheinungsjahr

n.n

Menü

Weitere Dienste

Einstellungen

A therapeutically targetable mechanism of BCR-ABL-independent imatinib resistance in chronic myeloid leukemia

Reducing the Risk for Transplantation-Related Mortality After Allogeneic Hematopoietic Cell Transplantation: How Much Progress Has Been Made?

Dasatinib treatment for Philadelphia chromosome‐positive leukemias

Ruxolitinib: a steroid sparing agent in chronic graft-versus-host disease

Sustained Complete Molecular Remission After Discontinuation of Tyrosine Kinase Inhibitors in Blast-Phase Chronic Myeloid Leukemia

Does the frequency of molecular monitoring after tyrosine kinase inhibitor discontinuation affect outcomes of patients with chronic myeloid leukemia?

Predicting early blast transformation in chronic‐phase chronic myeloid leukemia: Is immunophenotyping the missing link?

Allogeneic transplantation for advanced acute myelogenous leukemia: The value of complete remission

Bosutinib treatment for Philadelphia chromosome-positive leukemias

Chronic Myeloid Leukemia: What Every Practitioner Needs to Know in 2017

Long-term bosutinib (BOS) for Philadelphia Chromosome–Positive (Ph+) advanced (ADV) chronic myeloid leukemia (CML) after prior tyrosine kinase inhibitor (TKI) failure

Costs associated with induction chemotherapy in adult acute myeloid leukemia (AML) managed in a tertiary care specialized unit

Five-year results of the ponatinib phase II PACE trial in heavily pretreated CP-CML patients (pts)

A phase I, first-in-human study of MGD006/S80880 (CD123 x CD3 DART) in AML/MDS

Early diagnosis of acute myeloid leukemia by computed tomography scan

Phase 1 dose escalation trial of ilorasertib, a dual Aurora/VEGF receptor kinase inhibitor, in patients with hematologic malignancies

Landmark analysis of overall survival (OS) in patients with chronic (CP) or accelerated (AP) phase chronic myeloid leukemia (CML) treated with omacetaxine mepesuccinate

Elevated blood pressure (BP) and adverse events (AEs) of hypertension (HTN) in ponatinib (PON) leukemia trials

Long-term bosutinib (BOS) in patients (pt) with chronic phase (CP) chronic myeloid leukemia (CML) after prior imatinib (IM) failure

4-year results of the ponatinib phase II PACE trial in patients (pts) with heavily pretreated leukemia

Predictors of performing response monitoring in patients with chronic-phase chronic myeloid leukemia (CP-CML) in a prospective observational study (SIMPLICITY)

Long-term evaluation of vascular toxicity in patients with Ph+ leukemias treated with bosutinib

Phase I dose escalation study of TG02 in patients with advanced hematologic malignancies

Omacetaxine mepesuccinate in chronic phase chronic myeloid leukemia (CML-CP): A post hoc analysis of myelosuppression

Evolution of bosutinib (BOS) toxicity in patients (pts) with Ph+ leukemia after resistance/intolerance to prior therapy

Aktive Filter

Suchergebnisse filtern